Boster Immunoleader

antibody

Anti-Lipoprotein lipase Antibody

PA1304

100 ug/vial

200 USD

polyclonal

rabbit

human, mouse, rat, cow

Anti-Lipoprotein lipase Antibody

PA1304

Polyclonal

Rabbit IgG polyclonal antibody for Lipoprotein lipase(LPL) detection. Tested with WB in Human;Mouse;Rat;Bovine.

200 USD

Rabbit IgG

100 ug/vial

Lyophilized

No cross reactivity with other proteins.

Reacts with: bovine, human Predicted to work with: mouse, rat

WB

Concentration: 0.1-0.5μg/ml; Tested Species: Human, Bovine; Predicted Species: Mouse, Rat

Tested Species: In-house tested species with positive results. Predicted Species: Species predicted to be fit for the product based on sequence similarities. Other applications have not been tested. Optimal dilutions should be determined by end users.

A synthetic peptide corresponding to a sequence at the C-terminus of human Lipoprotein lipase(448-170aa EKVSHLQKGKAPAVFVKCHDKSL), different from the related mouse and rat sequences by two amino acids.

Each vial contains 5mg BSA, 0.9mg NaCl, 0.2mg Na2HPO4, 0.05mg Thimerosal, 0.05mg NaN3.

Immunogen affinity purified.

Add 0.2ml of distilled water will yield a concentration of 500ug/ml.

At -20˚C for one year. After reconstitution, at 4˚C for one month. It can also be aliquotted and stored frozen at -20˚C for a longer time. Avoid repeated freezing and thawing.

Boster provides a series of assays reacted with primary antibodies. Antibody can be supported by chemiluminescence kit EK1002 in WB.

Lipoprotein lipase(LPL) is the central enzyme in plasma triglyceride hydrolysis and is secreted by macrophages in the subendothelial space. Evidence has been provided that LPL produced by macrophages in the vessel wall exerts proatherogenic effects. Lipoprotein lipase has been difficult to purify, and its protein sequence remained undetermined until it could be deduced from the nucleotide sequence of its cDNA. The gene encodes a protein of 475 amino acids that becomes a mature protein of 448 residues after cleavage of a signal peptide. Analysis of the sequence indicated that human lipoprotein lipase, hepatic lipase, and pancreatic lipase are members of a gene family. The atherogenic effects of LPL have been mainly attributed to its ability to favor lipid accumulation within macrophages present in the atherosclerotic lesion.

1. Wion, K. L.; Kirchgessner, T. G.; Lusis, A. J.; Schotz, M. C.; Lawn, R. M. : Human lipoprotein lipase complementary DNA sequence. Science 235: 1638-1641, 1987. 2. Gotoda T., Senda M., Gamou T., Furuichi Y., Oka K.;Nucleotide sequence of human cDNA coding for a lipoprotein lipase (LPL) cloned from placental cDNA library."; Nucleic Acids Res. 17:2351-2352(1989). 3. Lo, J. Y.; Smith, L. C.; Chan, L. : Lipoprotein lipase: role of intramolecular disulfide bonds in enzyme catalysis. Biochem. Biophys. Res. Commun. 206: 266-271, 1995. 4. Lopez-Miranda, J.; Cruz, G.; Gomez, P.; Marin, C.; Paz, E.; Perez-Martinez, P.; Fuentes, F. J.; Ordovas, J. M.; Perez-Jimenez, F. : The influence of lipoprotein lipase gene variation on postprandial lipoprotein metabolism. J. Clin. Endocr. Metab. 89: 4721-4728, 2004.

LPL

Lipoprotein lipase(LPL)

lipoprotein lipase

EC 3.1.1 antibody EC 3.1.1.34 antibody HDLCQ11 antibody LIPD antibody LIPL_HUMAN antibody Lipoprotein lipase antibody LPL antibody LPL protein antibody MGC137861 antibody

P06858